Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial
Objective To evaluate the clinical efficacy and safety of leflunomide (L) added to the standard-of-care (SOC) treatment in COVID-19 patients hospitalised with moderate/critical clinical symptoms.Design Prospective, open-label, multicentre, stratified, randomised clinical trial.Setting Five hospitals...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-04-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/4/e068179.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|